Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 109 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Restless Legs Syndrome (RLS) Clear all
Not listed Phase 4 Interventional

An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS

NCT02560766
View directory record Official record
Conditions
RLS
Interventions
HORIZANT 300 mg, HORIZANT 600 mg, Placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
12
States / cities
Redwood City, California • Gulf Breeze, Florida • Winter Park, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 4, 2026, 5:44 PM EDT
Not yet recruiting Not applicable Interventional

The Effect of Dry Needling With Electrical Stimulation on Individuals With Restless Legs Syndrome

NCT05860751
View directory record Official record
Conditions
Neck Pain
Interventions
Dry Needling with electrical stimulation
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 4, 2026, 5:44 PM EDT
Not listed Phase 4 Interventional

Pitolisant in Refractory Restless Legs Syndrome

NCT05581576
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Pitolisant
Drug
Lead sponsor
William Ondo, MD
Other
Eligibility
21 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 4, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome

NCT01495793
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
12
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 4, 2026, 5:44 PM EDT
Completed No phase listed Observational

Neuronal Ceroid Lipofuscinosis and Associated Sleep Abnormalities

NCT01966757
View directory record Official record
Conditions
Neuronal Ceroid Lipofuscinosis, Batten's Disease
Interventions
Not listed
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Oct 4, 2026, 5:44 PM EDT
Completed Phase 3 Interventional Results available

Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance

NCT00748098
View directory record Official record
Conditions
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions
GSK1838262 Extended Release Tablets, Placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
24
States / cities
Jasper, Alabama • San Diego, California • Hallandale, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 4, 2026, 5:44 PM EDT
Recruiting Not applicable Interventional

Peroneal Electrical Nerve Stimulation in Pregnancy for Restless Legs Syndrome

NCT07144631
View directory record Official record
Conditions
Restless Leg Disorder, Restless Leg Syndrome (RLS), Pregnancy, Sleep Disorder (Disorder)
Interventions
Peroneal Nerve Stimulation (PNS) Device
Device
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 4, 2026, 5:44 PM EDT
Completed No phase listed Observational

New Data Analysis Methods for Actigraphy in Sleep Medicine

NCT00949858
View directory record Official record
Conditions
Obstructive Sleep Apnea, Restless Leg Syndrome, Insomnia
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 4, 2026, 5:44 PM EDT
Not listed Phase 4 Interventional

Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome

NCT02424695
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Gabapentin Enacarbil (GEn), Placebo
Drug
Lead sponsor
Cleveland Sleep Research Center
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Middleburg Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Oct 4, 2026, 5:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comprehensive Police Fatigue Management Program

NCT00246051
View directory record Official record
Conditions
Sleep Disorders, Sleep Apnea, Obstructive, Restless Legs Syndrome, Sleep Disorders, Circadian Rhythm, Sleep Initiation and Maintenance Disorders
Interventions
Sleep Hygiene Education, Expert-Led Sleep Disorders Screening and Treatment, Online Sleep Disorders Screening
Behavioral · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
683 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced Oct 4, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients

NCT00676403
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
placebo, Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Tuscaloosa, Alabama • Little Rock, Arkansas • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 4, 2026, 5:44 PM EDT
Completed Phase 3 Interventional Results available

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

NCT00256854
View directory record Official record
Conditions
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions
Ropinirole IR 1 mg, Ropinirole IR 2 mg, Ropinirole IR 1 mg Placebo, Ropinirole IR 2 mg Placebo, Ropinirole CR 2 mg, Ropinirole CR 3 mg, Ropinirole CR 2 mg Placebo, Ropinirole CR 3 mg Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
30
States / cities
Laguna Hills, California • Oxnard, California • Pasadena, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 4, 2026, 5:44 PM EDT
Completed Phase 4 Interventional

A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS

NCT00375284
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Pramipexole
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
52
States / cities
Birmingham, Alabama • Dothan, Alabama • Mesa, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 4, 2026, 5:44 PM EDT
Completed Phase 3 Interventional Results available

Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)

NCT01569464
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • Jasper, Alabama • Gilbert, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2014 · Synced Oct 4, 2026, 5:44 PM EDT
Recruiting Not applicable Interventional

Blood Changes After Exercise in Restless Legs Syndrome

NCT06481176
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
12-Week RLS Exercise Program
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 4, 2026, 5:44 PM EDT
Completed Phase 3 Interventional

Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome

NCT00355641
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Ropinirole Extended Release (XR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
59
States / cities
Alabaster, Alabama • Jasper, Alabama • Mesa, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 4, 2026, 5:44 PM EDT
Terminated Phase 2 Interventional Results available

Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia

NCT02826681
View directory record Official record
Conditions
Restless Legs Syndrome (RLS)
Interventions
Injectafer® (Ferric Carboxymaltose - FCM), Placebo (Normal Saline)
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Lemon Grove, California • Fort Myers, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 4, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome

NCT01498120
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
13 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Spring Hill, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 4, 2026, 5:44 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)

NCT01521663
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
IPX159, Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Brimingham, Alabama • Little Rock, Arkansas • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 4, 2026, 5:44 PM EDT
Terminated Phase 4 Interventional

Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome

NCT02117076
View directory record Official record
Conditions
Restless Leg Syndrome
Interventions
Gabapentin immediate release, Gabapentin enacarbil extended release
Drug
Lead sponsor
Theresa Zesiewicz, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 4, 2026, 5:44 PM EDT
Completed Phase 3 Interventional

RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole

NCT00314860
View directory record Official record
Conditions
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions
ropinirole Extended Release (XR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
28
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Oct 4, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Intravenous Iron Metabolism in Restless Legs Syndrome

NCT00685815
View directory record Official record
Conditions
Restless Legs
Interventions
Ferric Carboxymaltose (FCM), Placebo
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 4, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Simulated Driving Study in Restless Legs Syndrome

NCT01332318
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
XP13512, Diphenhydramine, Placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 4, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.

NCT01931878
View directory record Official record
Conditions
Restless Leg Syndrome
Interventions
incobotulinumtoxinA, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 4, 2026, 5:44 PM EDT